Moderna Inc (MIL:1MRNA)
€ 38.165 -0.445 (-1.15%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 44/100

Moderna Inc Vaccines Day Transcript

Mar 24, 2022 / 12:00PM GMT
Lavina Talukdar
Moderna, Inc. - Senior VP & Head of IR

Good morning, and welcome to Moderna's Third Annual Vaccines Day. Today, you will be hearing from our scientists and program leaders present data from our mRNA vaccines programs. You will also hear from distinguished key opinion leaders in Immunology and Vaccinology as it relates to SARS-CoV-2, influenza and latent viruses, including the association of EBV and multiple sclerosis.

Following the formal presentations, we will take your questions during the Q&A section. You can access the press release issued this morning as well as the presentation slides by going to the Investors section of our website. On today's call are Stephane Bancel, our Chief Executive Officer; Stephen Hoge, our President; Jacqueline Miller, Senior Vice President and Head of Infectious Diseases at Moderna; Raffael Nachbagauer, Program Leader for influenza vaccines; and Sumana Chandramouli, Program Lead for EBV vaccines.

Before we begin, please note that today's presentation will include forward-looking statements made pursuant to the safe harbor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot